Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • Ipsen accounts for 5.73 % of our European Portfolio. A trade is currently open since 10/10/2019 with a purchase price of € 69.46. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 40.16 EUR in weekly data.
  • The group's high margin levels account for strong profits.
  • With a P/E ratio at 8.44 for the current year and 7.81 for next year, earnings multiples are highly attractive compared with competitors.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The underlying tendency is negative on the weekly chart below the resistance at 68.45 EUR
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
IPSEN-38.48%4 474
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
NOVARTIS-16.30%180 007
PFIZER, INC.-21.13%171 422
NOVO NORDISK A/S-0.69%133 274
ELI LILLY AND COMPANY2.04%121 643
BRISTOL-MYERS SQUIBB COMPAN..-17.76%119 435
AMGEN INC.-17.75%116 941
ASTRAZENECA PLC-10.54%110 838
ABBVIE INC.-17.92%107 310
SANOFI-14.08%106 806
GLAXOSMITHKLINE-18.89%89 147
CHUGAI PHARMACEUTICAL CO., ..-7.80%58 774
ALLERGAN PLC-9.50%56 917
More Results
Financials (EUR)
Sales 2019 2 608 M
EBIT 2019 775 M
Net income 2019 465 M
Debt 2019 974 M
Yield 2019 2,25%
P/E ratio 2019 8,44x
P/E ratio 2020 7,81x
EV / Sales2019 1,92x
EV / Sales2020 1,71x
Capitalization 4 036 M
Upcoming event on IPSEN
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes